Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGL | P06737 | 16/20 | 1.00 |
| ▸ | PYGM | P11217 | 12/20 | 1.00 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.54 |
| ▸ | CCKAR | P32238 | 1/20 | 0.54 |
| ▸ | CCKBR | P32239 | 1/20 | 0.54 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4803861 | 0.90 | PYGL (1.00) | PYGLPYGM | |
| SCHEMBL4796608 | 0.90 | PYGL (1.00) | PYGLPYGM | |
| SCHEMBL4803919 | 0.90 | PYGL (1.00) | PYGLPYGM | |
| SCHEMBL14064277 | 0.85 | PYGL (0.73) | PYGLPYGMRIPK1CCKARCCKBR | |
| SCHEMBL6904531 | 0.83 | PYGL (0.71) | PYGLPYGMSMYD3 | |
| SCHEMBL4800465 | 0.81 | PYGL (0.71) | PYGLPYGMCCKARCCKBRSMYD3 | |
| SCHEMBL4803352 | 0.81 | PYGL (0.71) | PYGLPYGMRIPK1CCKARCCKBR | |
| SCHEMBL4799752 | 0.81 | PYGL (0.71) | PYGLPYGMRIPK1CCKARCCKBR | |
| SCHEMBL4800492 | 0.81 | PYGL (0.71) | PYGLPYGMCCKARCCKBRSMYD3 | |
| SCHEMBL5643030 | 0.79 | PYGL (0.77) | PYGLPYGMCCKARCCKBRSMYD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060128687-A1 | Lactam glycogen phosphorylase inhibitors and method of use | SHER PHILIP | 2006-06-15 | — | — | US | claimed |
| US-20040002495-A1 | Lactam glycogen phosphorylase inhibitors and method of use | BRISTOL-MYERS SQUIBB COMPANY | 2004-01-01 | — | — | US | claimed |
| US-7425550-B2 | Lactam glycogen phosphorylase inhibitors and method of use | BRISTOL-MEYERS SQUIBB COMPANY (US) | 2008-09-16 | — | — | US | disclosed |
| US-7098235-B2 | Triglyceride and triglyceride-like prodrugs of glycogen phosphorylase inhibiting compounds | BRISTOL-MYERS SQUIBB CO. (US) | 2006-08-29 | — | — | US | disclosed |
| US-20060128687-A1 | Lactam glycogen phosphorylase inhibitors and method of use | SHER PHILIP | 2006-06-15 | — | — | US | disclosed |
| US-7057046-B2 | Lactam glycogen phosphorylase inhibitors and method of use | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-06-06 | — | — | US | disclosed |
| US-20040142938-A1 | Triglyceride and triglyceride-like prodrugs of glycogen phosphorylase inhibiting compounds | BRISTOL-MYERS SQUIBB COMPANY | 2004-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040142938-A1 | Triglyceride and triglyceride-like prodrugs of glycogen phosphorylase inhibiting compounds | PYGL, PNLIP, PYGM | PYGL 1/4885PYGM 3/4885RIPK1 3009/4885 |
| US-20040002495-A1 | Lactam glycogen phosphorylase inhibitors and method of use | PYGL, PYGM, GYS2 | PYGL 1/4885PYGM 2/4885RIPK1 2251/4885 |
| US-20060128687-A1 | Lactam glycogen phosphorylase inhibitors and method of use | PYGL, PYGM, GYS1 | PYGL 1/4885PYGM 2/4885RIPK1 2109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.